Moderna has dosed the first patients in the Phase I study of mRNA-6231, the company’s mRNA-encoded IL-2, modified for the expansion of regulatory T cells.
mRNA-6231 is Moderna’s first autoimmune candidate to enter the clinic and its first subcutaneously administered therapeutic program.
“The initiation of the Phase I study of mRNA-6231 is an important milestone for Moderna, as we now look to bring the potential of mRNA therapeutics to people living with autoimmune diseases,” said Ruchira Glaser, Senior Vice President and Therapeutic Area Head, Rare Disease, Autoimmune & Cardiovascular. “This is our first mRNA autoimmune candidate, and the first to be subcutaneously administered. Today marks another important step in our mission to deliver on the promise of mRNA to help patients across diseases.”
